{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T09:14:51Z","timestamp":1769246091905,"version":"3.49.0"},"reference-count":29,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2021,7,30]]},"DOI":"10.1536\/ihj.20-671","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T22:08:50Z","timestamp":1626473330000},"page":"801-810","source":"Crossref","is-referenced-by-count":11,"title":["The Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Is Associated with the Recovered Ejection Fraction in Patients with Dilated Cardiomyopathy"],"prefix":"10.1536","volume":"62","author":[{"given":"Nobuyuki","family":"Enzan","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouji","family":"Matsushima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Ide","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Kaku","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Japan Community Healthcare Organization Kyushu Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Tohyama","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research, Kyushu University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouta","family":"Funakoshi","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research, Kyushu University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiki","family":"Higo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tsutsui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hellawell JL, Margulies KB. Myocardial reverse remodeling. Cardiovasc Ther 2012; 30: 172-81.","DOI":"10.1111\/j.1755-5922.2010.00247.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Punnoose LR, Givertz MM, Lewis EF, Pratibhu P, Stevenson LW, Desai AS. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail 2011; 17: 527-32.","DOI":"10.1016\/j.cardfail.2011.03.005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Florea VG, Rector TS, Anand IS, Cohn JN. Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the valsartan heart failure trial. Circ Heart Fail 2016; 9.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003123"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, <i>et al<\/i>. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol 2016; 1: 510-8.","DOI":"10.1001\/jamacardio.2016.1325"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. J\u00f8rgensen ME, Andersson C, Vasan RS, K\u00f8ber L, Abdulla J. Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: A systematic review and meta-analyses. Eur J Prev Cardiol 2018; 25: 366-76.","DOI":"10.1177\/2047487317750437"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Park CS, Park JJ, Mebazaa A, <i>et al<\/i>. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. J Am Heart Assoc 2019; 8: e011077.","DOI":"10.1161\/JAHA.118.011077"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Konstam MA. Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. Am J Cardiol 2005; 96: 867-71.","DOI":"10.1016\/j.amjcard.2005.05.037"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010; 56: 392-406.","DOI":"10.1016\/j.jacc.2010.05.011"},{"key":"9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/01.CIR.96.1.220","volume":"96","year":"1997","unstructured":"9. Danser AH, van Kesteren CA, Bax WA, <i>et al<\/i>. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 1997; 96: 220-6.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. St John Sutton M, Pfeffer MA, Plappert T, <i>et al<\/i>. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994; 89: 68-75.","DOI":"10.1161\/01.CIR.89.1.68"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Flather MD, Yusuf S, K\u00f8ber L, <i>et al<\/i>. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor myocardial infarction Collaborative Group. Lancet 2000; 355: 1575-81.","DOI":"10.1016\/S0140-6736(00)02212-1"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Granger CB, McMurray JJ, Yusuf S, <i>et al<\/i>. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-6.","DOI":"10.1016\/S0140-6736(03)14284-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.","DOI":"10.1056\/NEJM199108013250501"},{"key":"14","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1161\/01.CIR.91.10.2573","volume":"91","year":"1995","unstructured":"14. Greenberg B, Quinones MA, Koilpillai C, <i>et al<\/i>. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995; 91: 2573-81.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 2011; 57: 1468-76.","DOI":"10.1016\/j.jacc.2010.11.030"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Wong M, Staszewsky L, Latini R, <i>et al<\/i>. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002; 40: 970-5.","DOI":"10.1016\/S0735-1097(02)02063-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Leyrat C, Seaman SR, White IR, <i>et al<\/i>. Propensity score analysis with partially observed covariates: how should multiple imputation be used? Stat Methods Med Res 2019; 28: 3-19.","DOI":"10.1177\/0962280217713032"},{"key":"18","first-page":"e240","volume":"128","year":"2013","unstructured":"18. Writing Committee Members, Yancy CW, Jessup M, <i>et al<\/i>. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-327.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wilcox JE, Fonarow GC, Yancy CW, <i>et al<\/i>. Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. Am Heart J 2012; 163: 49-56.e2.","DOI":"10.1016\/j.ahj.2011.10.001"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lup\u00f3n J, D\u00edez-L\u00f3pez C, de Antonio M, <i>et al<\/i>. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail 2017; 19: 1615-23.","DOI":"10.1002\/ejhf.824"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc 2020; 9: e016219.","DOI":"10.1161\/JAHA.120.016219"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020; 382: 1653-9.","DOI":"10.1056\/NEJMsr2005760"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Francis GS, Tang WH. Beta-blockers and reverse remodeling: what are the implications? Am Heart J 2003; 145: 200-2.","DOI":"10.1067\/mhj.2003.106"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hori M, Nagai R, Izumi T, Matsuzaki M. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (Main-CHF II) study. Heart Vessels 2014; 29: 238-47.","DOI":"10.1007\/s00380-013-0340-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Woo GW, Petersen-Stejskal S, Johnson JW, Conti JB, Aranda JA, Curtis AB. Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study. J Interv Card Electrophysiol 2005; 12: 107-13.","DOI":"10.1007\/s10840-005-6545-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 1998; 40: 352-63.","DOI":"10.1016\/S0008-6363(98)00121-7"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Wittstein IS, Kass DA, Pak PH, Maughan WL, Fetics B, Hare JM. Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 38: 429-35.","DOI":"10.1016\/S0735-1097(01)01404-8"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Kotecha D, Holmes J, Krum H, <i>et al<\/i>. Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384: 2235-43.","DOI":"10.1016\/S0140-6736(14)61373-8"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Tobita T, Nomura S, Fujita T, <i>et al<\/i>. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep 2018; 8: 1998.","DOI":"10.1038\/s41598-018-20114-9"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/62\/4\/62_20-671\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T03:42:10Z","timestamp":1627702930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/62\/4\/62_20-671\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.20-671","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"article-number":"20-671"}}